Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

If you or someone you know has received a prostate cancer diagnosis, here's where to start, what to ask and how to plan ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

The fourth annual fundraiser, sponsored by the Institute for Prostate Cancer Research (IPCR), included both live and taped speeches from cancer survivors and their families as well as insights from ...

Stock image by PDPics from PixabayA Flinders University study shows that bowel cancer survivors face an elevated risk of ...

Most prostate cancer survivors surveyed reported feeling that telehealth cannot fully replace in-person visits, with perceptions varying significantly based on education level. The use of ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated its award-winning ArteraAI Prostate Test with new insights to help ...

Adverse events experienced by men with prostate cancer varied considerably based on the treatment they received, results of a 10-year follow-up study showed.The multicenter Comparative ...

Ralph Conwill is a Nashville resident, Vanderbilt graduate, prostate cancer survivor and advocate with doctors at VUMC. “If I only knew then what I know now.” How many of us have uttered that ...

When prostate cancer is confined to the primary tumor, survival is nearly 100%. When the cancer spreads, or metastasizes, the patient's chance of survival drops to less than 40%.

New guidelines have been developed for clinical follow-up care for prostate cancer survivors. The guidelines were published online in CA: A Cancer Journal for Clinicians. Ted A. Skolarus, M.D., M ...

If I need secondary treatment, I will call myself a patient living with cancer.” -Gogs Gagnon, a prostate cancer survivor and CURE® contributor. “‘Survivor’” works for me, but ‘patient’ is best when ...